View Item 

Impact of Gemcitabine Chemotherapy and 3-Dimensional Conformal Radiation Therapy/5-Fluorouracil on Quality of life of patients Managed for Pancreatic Cancer

Access Status
Open access
Authors
Short, Michelle
Goldstein, D.
Halkett, Georgia
Reece, W.
Borg, M.
Zissiadis, Y.
Kneebone, A.
Spry, Nigel
Date
2013
Type
Journal Article

Metadata
Show full item record
Citation
Short, M. and Goldstein, D. and Halkett, G. and Reece, W. and Borg, M. and Zissiadis, Y. and Kneebone, A. et al. 2013. Impact of Gemcitabine Chemotherapy and 3-Dimensional Conformal Radiation Therapy/5-Fluorouracil on Quality of life of patients Managed for Pancreatic Cancer. International Journal of Radiation: Oncology - Biology - Physics. 85 (1): pp. 157-162.
Source Title
International Journal of Radiation: Oncology - Biology - Physics
DOI
ISSN
School
WA Centre for Cancer and Palliative Care (WACCPC)
Remarks

NOTICE: this is the author’s version of a work that was accepted for publication in International Journal of Radiation Oncology/Biology/Physics. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in International Journal of Radiation Oncology/Biology/Physics, Vol. 85 (1): pp. 157-162.

URI
Collection
Abstract

Purpose: To report quality of life (QOL) results for patients receiving chemoradiation therapyfor pancreatic cancer.Methods and Materials: Eligible patients (nZ41 locally advanced, nZ22 postsurgery) enteredthe B9E-AY-S168 study and received 1 cycle of induction gemcitabine (1000 mg/m2 weekly 3with 1-week break) followed by 3-dimensional conformal radiation therapy (RT) (54 Gy locallyadvanced and 45 Gy postsurgery) and concomitant continuous-infusion 5-fluorouracil (5FU)(200 mg/m2/d throughout RT). After 4 weeks, patients received an additional 3 cycles of consolidationgemcitabine chemotherapy. Patients completed the European Organization for Researchand Treatment of Cancer QLQ-C30 and QLQ-PAN26 questionnaires at baseline, beforeRT/5FU, at end of RT/5FU, before consolidation gemcitabine, and at treatment completion.Results: The patterns of change in global QOL scores differed between groups. In the locallyadvanced group global QOL scores were þ13, þ8, þ3, and þ1 compared with baseline beforeRT/5FU (PZ.008), at end of RT/5FU, before consolidation gemcitabine, and at treatmentcompletion, respectively. In the postsurgery group, global QOL scores were 3, þ4, þ15,and þ17 compared with baseline at the same time points, with a significant improvement inglobal QOL before consolidation gemcitabine (PZ.03). No significant declines in globalQOL were reported by either cohort.